The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read Is BPC157 Legal? WADA, FDA Status, and What You Need to Know FDA mulls compounding for peptides previously flagged over safety risks BioSpace New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then,